We describe the case of a young female presenting with myalgia, mildly raised creatine kinase and a rash. The discussion emphasises the importance of a systematic approach to muscle symptoms, the value of a detailed hand examination and the importance of magnetic resonance imaging in the investigation of muscular symptoms.
1
Hyperthyroidism and more commonly hypothyroidism can both present with proximal myopathy. Patients with hyperthyroidism may also complain of weight loss, diarrhoea and heat intolerance. 1 Those with hypothyroidism commonly have an elevated creatinine kinase (CK).
Cushing's syndrome (endogenous and exogenous) is another differential for proximal myopathy. 1 Patients with Cushing's syndrome may have weight gain, striae, thinning of the skin, hirsuitism, acne and, in women, oligo-or amenorrhoea. 1 Alcohol excess can also cause proximal muscle weakness, but the patient was teetotal. 1 Viral myositis, for instance secondary to human immunodefi ciency virus (HIV) or infl uenza, is also a possible differential. 1 As no objective weakness was elicited, polymyalgia rheumatica was considered. 2 This can cause symptoms that are suggestive of proximal myalgia but it rarely affects those under the age of 50 years. 2 The symptoms are caused by referred pain from shoulders and hips; the muscles are not affected. 2 Infl ammatory markers are usually raised.
Metabolic myopathies, classically muscle phosphorylase defi ciency (McArdle disease), can present with weakness and poor exercise tolerance in adult life, but the history is usually chronic rather than acute. 2 Finally, infl ammatory myopathies, including dermatomyositis (DM), polymyositis (PM) and myositis associated with other autoimmune conditions, also produce proximal muscle weakness. 1 The peak incidence of DM and PM is between 40 and 50 years of age. 
Case progression
On the post-take ward round, clinicians felt that this woman had fatiguability and she also stated that her speech could be affected. A neurology opinion was requested to look at the possibility of myasthenia gravis. Concurrently, some bloods returned. The patient's thyroid function test was normal, her D-dimer was positive at 607 µg/l (normal range <500 µg/l) and her creatine kinase (CK) was mildly raised at 490 IU/l (normal range 25-200 IU/l). As she was breathless, with a positive D-dimer, a computed tomography pulmonary angiogram (CTPA) was performed, which excluded a pulmonary embolus. Myositis-associated antibodies were also measured.
Neurology review revealed no ptosis, swallowing or speech problems. It was concluded that there was limited evidence to support myasthenia gravis. A fasting lactate was normal, as was the patient's forced vital capacity (FVC) was normal at 3.29 l (predicted 3.27 l). She was, however, noted to have a non-blanching rash on her hands (Fig 1) . This had been present for several weeks and was previously diagnosed as a reactive dermatitis. The rheumatology team reviewed the patient and noted dilated nail fold capillaries and long cuticles with tiny infarcts (Fig 2) . The knuckle rash was felt to be consistent with Gottrons papules. The patient also demonstrated fatiguablity on stands test, managing only six stands from a sitting position without using her arms. She also became breathless during the test, though she did not desaturate. A diagnosis of dermatomyositis was made on clinical grounds. An urgent magnetic resonance imaging (MRI) scan of her shoulders showed extensive oedema throughout all muscle groups, consistent with myositis (Fig 3) . Anti-nuclear antibody was positive at titre 1/320. Further immunology, including anti Jo-1 and extended myositis panel, was negative. Treatment with prednisolone 30 mg daily was started, with a rapid but not complete fall in CK levels. These levels improved to normal (43 IU/l) with resolution of MRI changes (Fig 4) following the introduction of methotrexate 15 mg weekly and a temporary increase in prednisolone to 60 mg daily. Electromyography (EMG) 2 weeks after the start of treatment was normal. Because of a family history of breast cancer, the patient had a mammogram and pelvic ultrasound, both of which were normal.
Discussion
Dermatomyositis is one of the idiopathic infl ammatory myopathies; the others being polymyositis, immune-mediated necrotising myopathy and inclusion body myositis. 3 It is more common in females than in males (2:1) with a peak incidence between the ages of 40 and 50 years, though it can affect any age group. 4 Skin manifestations include a heliotrope rash (a purplish discolouration of the eyelids) and Gottrons papules, a violaceous rash that is prominent over the metacarpophalangeal or interphalangeal joints. 1 This rash is pathognomonic for dermatomyositis and may precede or accompany the weakness. 3 In contrast to the rash seen in systemic lupus erythematosus (SLE), this rash spares the phalanges. 4 Other skin manifestations may include the shawl sign, an erythematous macular sun sensitive rash on the upper back, or the V sign, a rash on the anterior chest, face and neck. 4 More subtle hand signs include periungual telangiectasiae and hypertrophy of the cuticles. A sub group of patients, those with amyopathic dermatomyositis, present with skin features alone without weakness or elevated enzymes. Dermatomyositis classically affects the proximal skeletal muscles. 4 Patients may describe diffi culty standing from a squatting position or climbing stairs. 4 It is crucial to document FVC to assess the degree of respiratory muscle involvement. In our case, we felt that the patient's dyspnoea was probably secondary to increased aerobic effort secondary to her reduced functional muscle capacity. Other systems can be affected, including the joints, oesophagus and lungs. 1 Patients may also complain of arthritis, dysphagia and dyspnoea or cough secondary to interstitial lung disease. 1 Cardiomyopathy, though a less-frequent complication, may present with arrhythmias or congestive cardiac failure. 4 Cardiac troponin should therefore be checked in all patients. In severe cases, patients may present with pseudohaematuria resulting from myoglobulinaemia. 2 Initial investigations include tests for elevated muscle enzymes. The most sensitive test is that for CK; other tests that may indicate muscle necrosis include those for lactate dehydrogenase (LDH), aldolase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT).
1 CK is elevated in 70% of cases, but CK levels do not correlate to weakness and may be normal. 3 In our case, the patient's CK level initially appeared to be only mildly elevated, but based on subsequent levels, it was eventually raised tenfold. Myositis-specifi c antibodies can be helpful in categorising autoimmune infl ammatory myopathy syndromes. For instance, the presence of anti-synthetase antibodies, such as anti-Jo 1 antibodies, may be associated with interstitial lung disease and Raynaud phenomenon. 3 Muscle electrophysiology is not a diagnostic test but fi brillations and low-amplitude short-duration polyphasic potential may support the diagnosis. Muscle biopsy may show an infl ammatory cell infi ltrate, necrosis and phagocytosis of muscle fi bres, but this test is invasive and requires specialised histology expertise. 3 MRI is sensitive but not specifi c for autoimmune myositis. In certain clinical contexts, such as in this case, MRI can help to confi rm the diagnosis. 5 It can also be useful in identifying potential biopsy sites. 5 Dermatomyositis is associated with an increased risk of malignancy, and current recommendations are to investigate all those over 40 years who have dermatomyositis for breast, ovarian, lung and gastrointestinal-tract tumours specifi cally. 2 Because of this increased risk, a comprehensive history and physical examination is important. 1 Breast and pelvic examinations are recommended in women and testicular and prostate examinations in men. 3 A CT chest, abdomen and pelvis is recommended with the addition of a pelvic ultrasound and mammogram for women. 3 Colonoscopy is advisable for all those aged over 50 years. 3 Treatment for dermatomyositis consists of conservative measures including the use of sun-blocking agents and physical activity to maintain strength. 1 Corticosteroids are the fi rst-line treatment. 3 Second-line agents include methotrexate, azathioprine, mycophenolate mofetil and intravenous immunoglobulins.
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